Long-Term Assessment of Remyelinating Therapy

NCT02657915 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Optic Neuritis

Interventions

DRUG: Placebo
DRUG: BIIB033 100mg/Kg

Sponsor

Biogen